|
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes
|
Jul 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.
|
Sep 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Eltrombopag for refractory severe aplastic anemia: dosing, duration, long term outcomes and clonal evolution
|
Apr 2019
|
Blood
|
aplastic anemia
|
|
"Moderate" dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution.
|
Sep 2014
|
Blood
|
aplastic anemia
|
|
Initial experience with L-leucine therapy in myelodysplastic syndromes with associated chromosome 5q deletion.
|
May 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia
|
May 2017
|
Blood
|
acute myeloid leukemia (AML)
|
|
Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes
|
Jun 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Eltrombopag mobilizes iron in patients with aplastic anemia
|
Apr 2018
|
Blood
|
aplastic anemia
|
|
Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure
|
Jun 2016
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Thrombosis in paroxysmal nocturnal hemoglobinuria.
|
Apr 2013
|
Blood
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
